vs

Side-by-side financial comparison of Akamai Technologies (AKAM) and EXACT SCIENCES CORP (EXAS). Click either name above to swap in a different company.

Akamai Technologies is the larger business by last-quarter revenue ($1.1B vs $878.4M, roughly 1.2× EXACT SCIENCES CORP). Akamai Technologies runs the higher net margin — 7.8% vs -9.8%, a 17.6% gap on every dollar of revenue. On growth, EXACT SCIENCES CORP posted the faster year-over-year revenue change (23.1% vs 7.4%). Akamai Technologies produced more free cash flow last quarter ($234.9M vs $120.4M). Over the past eight quarters, EXACT SCIENCES CORP's revenue compounded faster (17.4% CAGR vs 5.3%).

Akamai Technologies, Inc. provides cloud services for securing, delivering, and optimizing content and business applications over the internet in the United States and internationally. The company offers cloud solutions to keep infrastructure, websites, applications, application programming interfaces, and users safe from various cyberattacks and online threats while enhancing performance. It also provides web and mobile performance solutions to enable dynamic websites and applications; media...

Exact Sciences Corporation is an American molecular diagnostics company based in Madison, Wisconsin, specializing in the detection of early-stage cancers. The company provides products for the detection and prevention of colorectal cancer, including Cologuard, the first stool DNA test for colorectal cancer, along with additional screening and precision oncological tests for other types of cancer.

AKAM vs EXAS — Head-to-Head

Bigger by revenue
AKAM
AKAM
1.2× larger
AKAM
$1.1B
$878.4M
EXAS
Growing faster (revenue YoY)
EXAS
EXAS
+15.8% gap
EXAS
23.1%
7.4%
AKAM
Higher net margin
AKAM
AKAM
17.6% more per $
AKAM
7.8%
-9.8%
EXAS
More free cash flow
AKAM
AKAM
$114.4M more FCF
AKAM
$234.9M
$120.4M
EXAS
Faster 2-yr revenue CAGR
EXAS
EXAS
Annualised
EXAS
17.4%
5.3%
AKAM

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AKAM
AKAM
EXAS
EXAS
Revenue
$1.1B
$878.4M
Net Profit
$85.1M
$-86.0M
Gross Margin
58.7%
70.1%
Operating Margin
8.7%
-9.4%
Net Margin
7.8%
-9.8%
Revenue YoY
7.4%
23.1%
Net Profit YoY
-39.2%
90.1%
EPS (diluted)
$0.57
$-0.45

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AKAM
AKAM
EXAS
EXAS
Q4 25
$1.1B
$878.4M
Q3 25
$1.1B
$850.7M
Q2 25
$1.0B
$811.1M
Q1 25
$1.0B
$706.8M
Q4 24
$1.0B
$713.4M
Q3 24
$1.0B
$708.7M
Q2 24
$979.6M
$699.3M
Q1 24
$987.0M
$637.5M
Net Profit
AKAM
AKAM
EXAS
EXAS
Q4 25
$85.1M
$-86.0M
Q3 25
$140.2M
$-19.6M
Q2 25
$103.6M
$-1.2M
Q1 25
$123.2M
$-101.2M
Q4 24
$139.9M
$-864.6M
Q3 24
$57.9M
$-38.2M
Q2 24
$131.7M
$-15.8M
Q1 24
$175.4M
$-110.2M
Gross Margin
AKAM
AKAM
EXAS
EXAS
Q4 25
58.7%
70.1%
Q3 25
59.3%
68.6%
Q2 25
59.1%
69.3%
Q1 25
58.7%
70.8%
Q4 24
59.4%
69.0%
Q3 24
59.3%
69.4%
Q2 24
58.9%
69.8%
Q1 24
60.0%
70.0%
Operating Margin
AKAM
AKAM
EXAS
EXAS
Q4 25
8.7%
-9.4%
Q3 25
15.7%
-3.0%
Q2 25
14.5%
-0.3%
Q1 25
15.2%
-13.6%
Q4 24
14.5%
-122.8%
Q3 24
7.0%
-5.6%
Q2 24
15.1%
-3.8%
Q1 24
16.9%
-16.7%
Net Margin
AKAM
AKAM
EXAS
EXAS
Q4 25
7.8%
-9.8%
Q3 25
13.3%
-2.3%
Q2 25
9.9%
-0.1%
Q1 25
12.1%
-14.3%
Q4 24
13.7%
-121.2%
Q3 24
5.8%
-5.4%
Q2 24
13.4%
-2.3%
Q1 24
17.8%
-17.3%
EPS (diluted)
AKAM
AKAM
EXAS
EXAS
Q4 25
$0.57
$-0.45
Q3 25
$0.97
$-0.10
Q2 25
$0.71
$-0.01
Q1 25
$0.82
$-0.54
Q4 24
$0.92
$-4.69
Q3 24
$0.38
$-0.21
Q2 24
$0.86
$-0.09
Q1 24
$1.11
$-0.60

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AKAM
AKAM
EXAS
EXAS
Cash + ST InvestmentsLiquidity on hand
$1.2B
$964.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$5.0B
$2.4B
Total Assets
$11.5B
$5.9B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AKAM
AKAM
EXAS
EXAS
Q4 25
$1.2B
$964.7M
Q3 25
$1.1B
$1.0B
Q2 25
$966.6M
$858.4M
Q1 25
$1.3B
$786.2M
Q4 24
$1.6B
$1.0B
Q3 24
$1.7B
$1.0B
Q2 24
$1.6B
$946.8M
Q1 24
$1.7B
$652.1M
Stockholders' Equity
AKAM
AKAM
EXAS
EXAS
Q4 25
$5.0B
$2.4B
Q3 25
$4.7B
$2.5B
Q2 25
$4.5B
$2.5B
Q1 25
$4.6B
$2.4B
Q4 24
$4.9B
$2.4B
Q3 24
$4.8B
$3.2B
Q2 24
$4.8B
$3.2B
Q1 24
$4.6B
$3.1B
Total Assets
AKAM
AKAM
EXAS
EXAS
Q4 25
$11.5B
$5.9B
Q3 25
$10.8B
$5.9B
Q2 25
$10.5B
$5.8B
Q1 25
$10.0B
$5.7B
Q4 24
$10.4B
$5.9B
Q3 24
$10.2B
$6.7B
Q2 24
$10.1B
$6.7B
Q1 24
$9.9B
$6.4B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AKAM
AKAM
EXAS
EXAS
Operating Cash FlowLast quarter
$366.6M
$151.7M
Free Cash FlowOCF − Capex
$234.9M
$120.4M
FCF MarginFCF / Revenue
21.5%
13.7%
Capex IntensityCapex / Revenue
12.0%
3.6%
Cash ConversionOCF / Net Profit
4.31×
TTM Free Cash FlowTrailing 4 quarters
$1.0B
$356.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AKAM
AKAM
EXAS
EXAS
Q4 25
$366.6M
$151.7M
Q3 25
$441.8M
$219.9M
Q2 25
$459.1M
$89.0M
Q1 25
$251.2M
$30.8M
Q4 24
$343.8M
$47.1M
Q3 24
$392.5M
$138.7M
Q2 24
$431.0M
$107.1M
Q1 24
$351.9M
$-82.3M
Free Cash Flow
AKAM
AKAM
EXAS
EXAS
Q4 25
$234.9M
$120.4M
Q3 25
$329.1M
$190.0M
Q2 25
$313.6M
$46.7M
Q1 25
$133.4M
$-365.0K
Q4 24
$250.9M
$10.7M
Q3 24
$279.7M
$112.6M
Q2 24
$340.0M
$71.2M
Q1 24
$258.1M
$-120.0M
FCF Margin
AKAM
AKAM
EXAS
EXAS
Q4 25
21.5%
13.7%
Q3 25
31.2%
22.3%
Q2 25
30.1%
5.8%
Q1 25
13.1%
-0.1%
Q4 24
24.6%
1.5%
Q3 24
27.8%
15.9%
Q2 24
34.7%
10.2%
Q1 24
26.2%
-18.8%
Capex Intensity
AKAM
AKAM
EXAS
EXAS
Q4 25
12.0%
3.6%
Q3 25
10.7%
3.5%
Q2 25
13.9%
5.2%
Q1 25
11.6%
4.4%
Q4 24
9.1%
5.1%
Q3 24
11.2%
3.7%
Q2 24
9.3%
5.1%
Q1 24
9.5%
5.9%
Cash Conversion
AKAM
AKAM
EXAS
EXAS
Q4 25
4.31×
Q3 25
3.15×
Q2 25
4.43×
Q1 25
2.04×
Q4 24
2.46×
Q3 24
6.78×
Q2 24
3.27×
Q1 24
2.01×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AKAM
AKAM

Security$592.4M54%
Delivery$311.1M28%
Cloud Computing$191.4M17%

EXAS
EXAS

Screening$695.1M79%
Precision Oncology$183.2M21%

Related Comparisons